Eklira® Genuair® Provides Significant Improvements In COPD Symptoms Vs Placebo In A 6-Week Study

New Phase IIIb data published in the journal COPD demonstrates comparable efficacy for twice-daily Eklira® Genuair® (aclidinium) vs tiotropium following the 6-week study1. The data show significant improvements in 24-hour bronchodilation for aclidinium vs placebo from day 1 of treatment1. Significant improvements in bronchodilation vs tiotropium were found on day 1 with comparable bronchodilation vs tiotropium at week 61...
Source: Health News from Medical News Today - Category: Consumer Health News Tags: COPD Source Type: news